<code id='AF7AF8A8C2'></code><style id='AF7AF8A8C2'></style>
    • <acronym id='AF7AF8A8C2'></acronym>
      <center id='AF7AF8A8C2'><center id='AF7AF8A8C2'><tfoot id='AF7AF8A8C2'></tfoot></center><abbr id='AF7AF8A8C2'><dir id='AF7AF8A8C2'><tfoot id='AF7AF8A8C2'></tfoot><noframes id='AF7AF8A8C2'>

    • <optgroup id='AF7AF8A8C2'><strike id='AF7AF8A8C2'><sup id='AF7AF8A8C2'></sup></strike><code id='AF7AF8A8C2'></code></optgroup>
        1. <b id='AF7AF8A8C2'><label id='AF7AF8A8C2'><select id='AF7AF8A8C2'><dt id='AF7AF8A8C2'><span id='AF7AF8A8C2'></span></dt></select></label></b><u id='AF7AF8A8C2'></u>
          <i id='AF7AF8A8C2'><strike id='AF7AF8A8C2'><tt id='AF7AF8A8C2'><pre id='AF7AF8A8C2'></pre></tt></strike></i>

          entertainment

          entertainment

          author:entertainment    Page View:1
          Sammy Kimball for STAT

          Who’s watching the drug price watchmen? Are RSV vaccines too expensive? And is it finally time for Novavax to shine?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Bob Herman joins us to explain his year-long investigation into some brazen conflicts of interest in the world of prescription drug pricing. Then, STAT’s Helen Branswell calls in to walk us through a news-packed week for vaccines, including weighty decisions for Covid-19 and RSV.

          advertisement

          For more on what we cover, here’s the story on conflicts of interest; here’s the latest on RSV vaccines; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          knowledge

          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more
          Paxlovid rebound happens. Why and to whom are still a mystery
          Paxlovid rebound happens. Why and to whom are still a mystery

          TheCovidantiviraldrugPaxlovidisdisplayedinNewYork.StephanieNano/APAsanemergencydepartmentphysicianin

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          Prescription digital therapeutics are key to pharma’s future

          AdobeFiveyearsfromnow,whenpatientswalkintoadoctor’sofficepresentingsymptomsofalmostanyconditionyouca